Actelion Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 4/5/2017)
| Balance Sheet | Total Assets | 2,200,429,539.62 | ROE | – |
| Balance Sheet | Total Equity | 1,325,500,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -59,542,214.39 | P/FCF | – |
| Cashflow | Free Cash Flow | 900,999,055.68 | – | – |
| Cashflow | Operating Cash Flow | 919,530,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 6.56 | Div. Yield | – |
| Income | Net Income | 727,444,991.35 | P/E | – |
| Income | Shares Outstanding | 107,811,000.00 | P/B | – |
| Income | Total Revenue | 2,417,940,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Actelion Ltd is a Switzerland-based biopharmaceutical company that focuses on the discovery, development and commercialization of drugs for diseases with unmet medical needs. The Company specializes in the field of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. Its portfolio of PAH treatments includes Opsumit (macitentan), Tracleer (bosentan), Uptravi (selexipag), Veletri (epoprostenol for injection) and Ventavis (iloprost). Opsumit is an orally available endothelin receptor antagonist (ERA). Tracleer is an orally available endothelin receptor antagonist (ERA). Uptravi is an oral, selective IP receptor agonist targeting the prostacyclin pathway in PAH. Veletri (epoprostenol for injection) is an intravenous prostacyclin. Ventavis is an inhaled formulation of iloprost, a synthetic compound similar to prostacyclin (PGI2).
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.actelion.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more